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Resumo
Introdução: Há indícios de que a proteína 
da soja poderia contribuir para reduzir a 
velocidade de progressão da doença renal, 
diminuindo colesterol sérico e proteinúria 
em pacientes com nefropatias. Este estudo 
foi desenvolvido para avaliar o efeito da die-
ta com proteína da soja sobre proteinúria e 
dislipidemia, em pacientes com glomerulopa-
tias proteinúricas. Pacientes e Métodos: Os 
pacientes foram divididos em três grupos: o 
Grupo Controle (n = 9) recebeu dieta com 
0,8 g/kg/dia de proteína animal; o Grupo de 
Estudo 1 (n = 9) recebeu dieta com 0,8 g/kg/
dia de proteína da soja e o Grupo 2 (n = 9), 
dieta com 0,8 g/kg/dia de proteína da soja 
mais fibras. O período de estudo foi de oito 
semanas. Durante o período basal e no final 
do estudo, os pacientes foram submetidos 
à avaliação laboratorial e antropométrica. 
Resultados: Não foram observadas diferen-
ças estatisticamente significantes entre os 
períodos pré e pós-intervenção em nenhum 
dos grupos estudados, nos parâmetros antro-
pométricos ou na composição corporal entre 
os três grupos, nem nos níveis de proteinúria 
(Controle: 0.7 ± 0.6 versus 0.8 ± 0.6; Grupo 
1: 2.0 ± 1.7 versus 1.9 ± 1.8; Grupo 2: 2.0 ± 
1.4 versus 2.1 ± 2.0). No entanto, observou-
se discreta diminuição nos níveis triglicérides 
(244.8+-275.9 versus 200.5+-34.0), coleste-
rol total (234.0+-59.4 versus 181.2+-110.3) 
e LDL (136.0+-59.1 versus 104.1+-39.4) no 
Grupo 1, embora sem atingir significância es-
tatística. Conclusão: Não foram detectados 
efeitos benéficos com a substituição da prote-
ína animal pela proteína da soja em relação 
aos objetivos de reduzir proteinúria e hiperli-
pidemia; porém, constatou-se que a dieta de 
proteína da soja não causou alterações de-
letérias na composição corporal, mantendo 
um estado nutricional adequado.
Palavras-chave: glomerulonefrite, alimentos 
de soja, proteinúria, dieta.
AbstRAct
Introduction: It has been suggested that 
soy protein can slow renal disease pro-
gression by decreasing plasma choles-
terol and proteinuria in patients with 
nephropathies. This study was designed 
to evaluate the effect of soy protein on 
proteinuria and dyslipidemia, in patients 
with proteinuric glomerulopathies. 
Patients and Methods: Patients were di-
vided into three groups: Control Group 
(n = 9) received diet with 0.8 g/kg/day of 
animal protein; Study Group 1 (n = 9), 
0.8 g/kg/day of soy protein; and Group 2 
(n = 9), 0.8 g/kg/day of soy protein plus 
fibers. The study period corresponded 
to eight weeks. During the baseline peri-
od and by the end of the study, patients 
were submitted to laboratorial and an-
thropometric evaluation. Results: There 
was no statistically significant difference 
between baseline and post-diet periods 
among the three groups in anthropo-
metric parameters or body composition, 
neither in proteinuria levels (Control: 
0.7 ± 0.6 versus 0.8 ± 0.6; Group 1: 2.0 
± 1.7 versus 1.9 ± 1.8; Group 2: 2.0 ± 
1.4 versus 2.1 ± 2.0). However, a slight 
decrease in triglycerides (244.8 ± 275.9 
versus 200.5 ± 34.0), total (234.0 ± 59.4 
versus 181.2 ± 110.3) and LDL (136.0 
± 59.1 versus 104.1 ± 39.4) cholesterol 
in Group 1 was observed, although not 
significant. Conclusion: We have not ob-
served beneficial effects when using soy 
protein instead of animal protein with 
the aim of attenuating proteinuria and 
hyperlipidemia, but we have shown that 
soy protein has not caused deleterious 
changes in body composition, ensuring 
an adequate nutritional state.
Keywords: glomerulonephritis, soy foods, 
proteinuria, diet.
Short-term effects of soy protein diet in patients with 
proteinuric glomerulopathies
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IntRoductIon
Proteinuric glomerulopathies are chronic kidney dis-
eases, which prognosis is particularly related to the 
levels of persistent urinary protein excretion. As the 
nephrotic condition is an extreme of the manifesta-
tions’ spectrum of the glomerular diseases, associated 
with more severe metabolic changes, it illustrates the 
context in which a nutritional therapeutic approach 
(evaluated in the present study) could contribute to 
the management of proteinuric glomerulopathies. 
The hallmark of nephrotic syndrome (NS) is the 
increased glomerular permeability to proteins, which 
leads to proteinuria. Homeostatic mechanisms are 
unable to cope with such urinary protein losses, 
and the resulting hypoalbuminemia frequently leads 
to edema.1,2 The glomerular damage that is charac-
teristic of NS can also result in urinary loss of lip-
ids and other plasma proteins, including some of the 
apolipoproteins.3
Another important feature of the NS is hyper-
lipidemia characterized by increased plasma concen-
trations of very-low-density (VLDL), intermediate-
density, low-density lipoproteins (LDL) and, as the 
disorder progresses, also by hypertriglyceridemia and 
decreased concentrations of high-density lipopro-
teins (HDL). Such lipid abnormalities may predis-
pose to more rapid progression of the renal disease.4 
Therefore, correction of lipid abnormalities or their 
prevention when possible, in patients with nephrot-
ic syndrome, could be a protective factor against its 
progression. 
It is noteworthy that persistent proteinuria is one 
of the most relevant prognostic factors determining 
progression of glomerular diseases. Therefore, reduc-
tion of proteinuria and maintenance of serum pro-
teins levels are important goals in the treatment of 
NS, as the protein traffic decrease would protect the 
kidney from the pro inflammatory consequences of 
the protein tubular overload determined by protein 
reabsorption.5,6 
Considering all these factors, it has been proven 
that individuals with NS and proteinuria need a spe-
cial diet, and protein is the nutrient that deserves a 
particular emphasis in the nutritional management of 
these patients.7
There is abundant evidence that changing the 
amount of diet protein exerts a profound influence 
on renal function and course of renal disease. High 
protein intake has long been known to aggravate re-
nal injury and accelerate the progression of chronic 
kidney disease, whereas low protein intake produces 
the opposite effects.4,8-10
According to Azadbakht et al.,11 an usual diet pre-
scribed for NS and proteinuria has 0.8 g/kg of body 
weight, per day, with 70% of animal protein in its com-
position. In addition, there is evidence that changing 
the source or type of dietary protein may have a benefi-
cial effect on renal function and renal disease.8,12-14 The 
protein of animal origin, for example, seems to exert a 
deleterious effect on renal function.15 This is supported 
by nutritional intervention studies in animals and hu-
mans, showing that the replacement of animal protein 
with vegetable protein in the diet reduces proteinuria 
and preserves renal function.3,8,12-14
Meal studies indicate that soy protein does not 
alter post-prandial renal blood flow or glomerular 
filtration rates, whereas the animal one significantly 
increases these indexes. Long-term intakes of soy-
protein diets were associated with lower renal blood 
flow, glomerular filtration rate, and fractional clear-
ance of albumin than those of animal-protein diets. 
Of interest in this area, vegan and lactoovovegetarian 
subjects without renal disease had lower glomerular 
filtration rates and less urinary albumin excretion 
than omnivores.16
Long-term studies also indicate that soy-protein 
intake protects kidneys, whereas excessive animal-
protein intake may be harmful to kidneys. In animal 
models of kidney diseases, rats fed with soy protein 
had much slower progression of renal disease than did 
rats fed with casein. Human studies have not been op-
timally controlled, but they suggest that substituting 
soy protein for animal protein decreases proteinuria 
in individuals with chronic glomerular disease.16
Soy protein is a vegetable protein that sustains ad-
equate growth rate in rats and infants. It has an ami-
no acid profile that meets the requirement for each 
one in humans and rats to growth and maintenance. 
Therefore, soy protein is considered to be a complete 
protein, with a protein digestibility-corrected amino 
acid score of 1; it also has a high arginine/lysine ra-
tio, which is associated with lower insulin secretion 
compared to protein of animal origin. Afterwards, 
soy protein contains isoflavones, which act as weak 
estrogens, inhibiting tyrosine kinase-dependent sig-
nal transduction processes and functioning as cellular 
antioxidants.3 Anderson et al.,17 in a meta-analysis, 
showed that the consumption of soy protein signifi-
cantly decreased serum concentrations of total cho-
lesterol, LDL cholesterol, and triglycerides (TG) with 
a larger decrease in subjects with moderate or severe 
hypercholesterolemia. 
Considering recent evidence related to the benefi-
cial effects of soy protein on proteinuria reduction, as 
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well as on hyperlipidemia correction, more detailed 
studies are necessary to better evaluate such improv-
ing effects in patients with the NS. An additional ap-
plication of the soy protein prescription may be pro-
teinuric glomerular diseases in which antiproteinuric 
drugs could not be administered.
Therefore, the aim of the present study was to 
evaluate whether soy protein decreases proteinuria 
and hyperlipidemia in patients with proteinuric glom-
erulonephritis in short-term.
PAtIents And methods
subjects
We have evaluated 27 adult patients (23 of them 
were female), with proteinuria and normal or slight-
ly altered renal function, from the Glomerulopathy 
Section of Universidade Federal de São Paulo – Escola 
Paulista de Medicina, in Brazil.
The inclusion criteria involved the diagnosis of: 
primary glomerulopathy, and serum creatinine < 2.0 
mg/dL (and creatinine clearance > 50 mL/minutes) by 
the time of the first nutritional evaluation. The selected 
patients could be in the course of a treatment for pro-
teinuric glomerulonephritis, without response, or they 
could initiate treatment by this dietitian approach. In 
the first condition, immunosuppressive drugs were 
interrupted when results were considered inadequate; 
then, two months after total drug withdrawal, the pa-
tient became eligible to participate in the present study. 
Nevertheless, the use of antiproteinuric medication, as 
angiotensin converting enzyme (ACE) inhibitors, and 
angiotensin receptor blockers, could be maintained 
during the study both by their renoprotective or anti-
hypertensive actions. Failure of such antiproteinuric 
treatment was defined when, after three different pro-
teinuria determination separated by one month inter-
val, no decrease of proteinuria levels was observed. 
Besides, during this study, it was not permitted to 
increase the dosage of such drugs; patients should be 
under adequate blood pressure control by the time of 
inclusion in the study, but in case of uncontrolled hy-
pertension during the study period, other drugs were 
utilized to control blood pressure levels.
Patients were excluded of the study if a secondary 
glomerulopathy was diagnosed and in the event of non-
compliance (especially if related to the oriented diet).
study prOtOcOl
A prospective, randomized, controlled, clinical study 
was performed. After meeting the inclusion criteria 
and providing the informed written consent, all pa-
tients were instructed to eat an animal protein diet 
(APD) during one month. At the initial period of ob-
servation, after admission to the study, patients main-
tained their previous treatment and were submitted 
to a clinical evaluation, the laboratory exams were 
performed (24-hour proteinuria, urinalysis, 24-hour 
urinary urea, creatinine clearance, hemoglobin, he-
matocrit, serum iron, transferrin, albumin, calcium, 
phosphorus, cholesterol, TG, serum and urinary po-
tassium, sodium and phosphorus).
After this period, patients were randomly allo-
cated to three groups. The groups were as follows: 
Control, APD; Group 1, vegetable protein diet (VPD) 
that received Previna (nutritional composition in 
Appendix A); and Group 2, VPD with fiber (VPD + 
F) that received Sanavita (nutritional composition in 
Appendix B).
During the period of study, after the initial phase, 
patients were submitted to a complete physical exam-
ination of anthropometric parameters, measures of 
body composition, and a food diary of three days.
diet
The patients were carefully instructed by a skilled di-
etitian about the corresponding diet. The APD diet 
consisted on 0.8 g/kg/d of animal origin protein, pa-
tients assigned to VPD and VPD+F Groups were pre-
scribed a 0.8 g/kg/d of vegetal origin protein diet. For 
all groups, energy prescription was 30 kcal/kg of ideal 
body weight/day, with 60% of high biological value 
proteins, and reposition of 1 g/day of protein for each 
gram of nutrient lost by the urine.
nutritiOnal assessment
Dietary assessment
Energy, macronutrients (protein, carbohydrate and 
lipids) and micronutrients (calcium, phosphorus, iron 
and cholesterol) intake were estimated from a three-
day food diary (not at the week end), using a comput-
er software developed at UNIFESP and at the United 
States of America Department of Agriculture18 table 
as the nutrient data base. Protein intake was also es-
timated from the normalized protein equivalent of 
nitrogen appearance (nPNA), determined according 
to the formula of Sargent e Gotch,19 using a 24-hour 
urinary urea excretion. 
anthropometric Data anD boDy composition
The following anthropometric parameters were 
evaluated: body weight and height. Body mass in-
dex (BMI) was calculated as body weight divided by 
squared height. The cutoff points used were as recom-
mended by the World Health Organization.20 Body 
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composition was also evaluated using bioelectrical 
impedance analysis (BIA), which was performed us-
ing a single frequency tetrapolar technique (800A, 50 
kHz, BIA 101 Quantum, RJL Systems, Detroit, USA). 
The software Fluids & Nutrition (version 3.0), pro-
vided by the manufacturer, was used to estimate the 
body composition.
Laboratory Data
The patients had blood drawn under fasting condi-
tions. Twenty-four urine collection were obtained to 
measure urinary protein excretion and to evaluate 
glomerular filtration rate, using standard creatinine 
clearance corrected for the body surface area (1.73 
m²). These and the following parameters were meas-
ured on a monthly basis, and also after two months: 
urinary urea, phosphorus and sodium, serum creati-
nine, urea, albumin, cholesterol and TG, sodium and 
potassium, hemoglobin, hematocrit, and transfer-
rin. Laboratory tests were performed in the Central 
Laboratory of the Nephrology Division of UNIFESP.
statistical analysis
Nonparametric tests were applied. The Wilcoxon test 
was used to compare the results obtained after animal 
and soy diet (post-diet period) versus baseline peri-
od (pre diet) within the same group. It was used the 
statistical software Sigma-Stat, version 2.0. Results 
were shown as mean and standard deviation (X ± 
SD). Statistical significance was defined as p < 0.05.
Results
Twenty-seven patients with proteinuric glomerulop-
athies were evaluated, with a mean age of 46 ± 12 
years-old.
Table 1 shows the means of the ingestion of calo-
ries, macronutrients (protein, lipids and carbohy-
drates) and micronutrients (calcium, iron, sodium 
and potassium) in baseline and post-diet periods in 
the three groups. It was observed a significant de-
crease in the energetic intake from the baseline to the 
post-diet period in the three groups (30.6 ± 6.7 versus 
21.7 ± 6.0; 30.4 ± 5,6 versus 24.6 ± 4.3 and 28.8 
± 7.8 versus 24.9 ± 4.2 kcal/kg/d, respectively). The 
same behavior was observed in lipids (48.4 ± 11.2 
versus 42.6 ± 13.5; 52.3 ± 23.1 versus 30.5 ± 14.6 
and 43.5 ± 17.4 versus 26.9 ± 6.5 g/d, respectively), 
and proteins (1.3 ± 0.3 versus 1.0 ± 0.4; 1.2 ± 0.2 
versus 1.0 ± 0.3 and 1.2 ± 0.4 versus 0.9 ± 0.2 g/
kg/d, respectively) ingestion in the three groups. But 
the carbohydrate ingestion revealed a significant de-
crease only in the Control Group (279.7 ± 115.1 ver-
sus. 165.7 ± 48.5 g/d). Nevertheless, in opposition to 
what was observed through the food diary, when the 
Intake
Control Group 
(Animal protein) 
(n = 9)
Study Group 1  
(Soy) 
(n = 9)
Study Group 2 
(Soy + Fibers) 
(n = 9)
Pre Post Pre Post Pre Post
Energy (kcal/d) 1,859 ± 571 1,287 ± 319* 1,753 ± 383 1,412 ± 270* 1,609 ± 315 1,412 ± 216*
Energy (kcal/
kg/d)
30.6 ± 6.7 21.7 ± 6.0* 30.4 ± 5.6 24.6 ± 4.3* 28.8 ± 7.8 24.9 ± 4.2*
Protein (g/d) 77.5 ± 23.7 61.4 ± 21.7* 72.3 ± 17.4 60.1 ± 16.4* 70.5 ± 23.3 53.6 ± 14.9*
Protein (g/kg/d) 1.3 ± 0.3 1.0 ± 0.4* 1.2 ± 0.2 1.0 ± 0.3* 1.2 ± 0.4 0.9 ± 0.2*
PNA 0.9 ± 0.3 0.9 ± 0.2 0.8 ± 0.3 0.8 ± 0.1 0.7 ± 0.2 0.7 ± 0.1
Lipids (g/d) 48.4 ± 11.2 42.6 ± 13.5* 52.3 ± 23.1 30.5 ± 14.6* 43.5 ± 17.4 26.9 ± 6.5*
Carbohydrate 
(g/d)
279.7 ± 115.1 165.7 ± 48.5* 250.3 ± 65.1 229.7 ± 51.0 236.9 ± 58.8 243.8 ± 41.9
Iron (mg/d) 14.9 ± 5.1 9.4 ± 3.2 12.0 ± 2.9 13.5 ± 1.7 13.5 ± 4.5 15.7 ± 3.9
Calcium (mg/d) 603.2 ± 121.3 581.5 ± 115.5 756.3 ± 431.0 925.9 ± 179.0 640.4 ± 299.2 352.0 ± 128.5*
Phosphorus 
(mg/d)
1009.5 ± 258.9 864.7 ± 198.8 1093.2 ± 331.1 908.4 ± 199.0 1072.6 ± 317.9 1029.1 ± 254.5
Cholesterol 
(mg/d)
167.4 ± 61.1 155.9 ± 70.4 146.0 ± 58.7 74.2 ± 113.9* 185.2 ± 62.3 78.2 ± 93.3*
Table 1 intake Of calOries, macrOnutrients and micrOnutrients in baseline and pOst-diet periOds in the 
three grOups (cOntrOl, sOy and sOy + fibers)
X ± SD, *p < 0.05 versus pre; PNA: equivalent of protein nitrogen appearance.
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protein ingestion was evaluated by PNA, no group 
showed significant decrease. Considering micronutri-
ents, a significant decrease in calcium ingestion was 
observed only in the Study Group 2 (640.4 ± 299.2 
versus. 352.0 ± 128.5 mg/d). The cholesterol ingestion 
presented a significant decrease in the Study Groups 1 
and 2 (146.0 ± 58.7 versus. 74.2 ± 113.9 and 185.2 ± 
62.3 versus 78.2 ± 93.3 mg/d).
The Table 2 shows the means of the anthropomet-
ric parameters and body composition of the patients 
in the Control, Soy, and Soy + Fibers Groups. It was 
not observed any statistical difference related to the 
anthropometric parameters between baseline and 
post-diet periods in all the groups. As concerned to 
body composition, it was not observed any difference 
between muscle mass and fat mass between baseline 
and post-diet periods in all groups. The Study Group 
2 presented a significantly lower body water value in 
post-diet period than in the baseline (34.4 ± 6.9 ver-
sus 33.3 ± 6.7 kg).
Table 3 shows the means of laboratory parame-
ters of the three groups’ patients. It was not observed 
any statistical difference of protein excretion levels 
between baseline and post-diet periods in all groups. 
The other laboratory parameters were not statisti-
cally different between baseline and post-diet periods, 
except for hemoglobin and serum urea in the Soy 
Group, which presented a significant decrease (14.1 
± 1.5 versus 13.4 ± 1.4 g/dL and 36.8 ± 13.5 versus 
31.7 ± 15.2 mg/dL), and serum sodium that presented 
a significant increase (137.2 ± 2.3 versus 139.2 ± 1.8 
mEq/L). A slight decrease of TG, total and LDL cho-
lesterol was observed at the post-diet period versus 
baseline in the Study Group 1, although this differ-
ence has not been significant.
The Figures 1, 2, 3 and 4 show the individual val-
ues of the 24-hour proteinuria, total and LDL cho-
lesterol and TG of the patients in the three groups, 
respectively, where each point represents a patient.
dIscussIon
We have chosen to evaluate soy diet in the present 
study, because it is considered a unique food, and 
contains several nutrients (complex carbohydrates, 
vegetal protein, soluble and insoluble fibers, oligosac-
charides, fitochemistries – especially isoflavones, and 
minerals). The oligosaccharides present in soy are re-
sponsible by part of its peculiar profile, as they are 
not hydrolyzed in the bowel, being fermented to short 
chain fatty acids that inhibit the cholesterol synthe-
sis. Besides, soy is considered one of the main sources 
of soluble fibers, which decrease significantly serum 
cholesterol and glucose, and of the insoluble fibers 
that contribute to the gastrointestinal function. 
Different studies have shown that the use of soy pro-
tein may slow progression of chronic renal disease8,21 
by decreasing hyperfiltration and proteinuria.22
In the present study, aiming to evaluate the short-
term effect of “soy protein”, with the intention of re-
ducing proteinuria and dyslipidemia in patients with 
proteinuric glomerulopathies, we compared a diet 
with protein of animal origin (0.8 g/kg/day, a conven-
tional diet) to a diet with soy protein (0.8 g/kg/day).
When energetic and macronutrients ingestion was 
evaluated, through the food diary of three days in 
Table 2 intake Of calOries, macrOnutrients and micrOnutrients in baseline and pOst-diet periOds in the 
three grOups (cOntrOl, sOy and sOy + fibers)
Variables
Control Group 
(Animal protein) 
(n = 9)
Study Group 1 
(Soy) 
(n = 9)
Study Group 2 
(Soy + Fibers) 
(n = 9)
Pre Post Pre Post Pre Post
Age (years) 46.0 ± 12.1 41.8 ± 12.7 43.1 ± 15.2
Weight (kg) 70.5 ± 18.4 69.4 ± 17.9* 60.5 ± 14.7 58.3 ± 12.1 57.8 ± 22.5 61.0 ± 11.5
BMI (kg/m²) 26.7 ± 5 26.1 ± 5.1 24.1 ± 5.7 23.1 ± 4.8 24.8 ± 3.2 24.4 ± 3.1
Body water (kg) 33.4 ± 4.5 33.1 ± 3.7 33.3 ± 6.7 33 ± 6 34.4 ± 6.9 33.3 ± 6.7*
Body water (%) 51.9 ± 5.3 52 ± 5.7 57.7 ± 7.1 57.0 ± 5 55.4 ± 7.7 54.9 ± 5.7
Fat-free mass(kg) 45.7 ± 5.9 45.1 ± 5.3 45.6 ± 9.2 45.0 ± 8.2 46.8 ± 9.4 45.5 ± 9.3
Fat-free mass (%) 70.7 ± 7.5 71.1 ± 8.1 76.3 ± 8.1 77.9 ± 6.5 75.9 ± 10.2 74.8 ± 7.4
Fat mass(kg) 19.0 ± 5.7 18.7 ± 6.3 14.8 ± 7.2 13.3 ± 5.5 15.5 ± 8 15.4 ± 5.8
Fat mass(%) 29.2 ± 7.5 28.9 ± 8.11 23.7 ± 8.1 22.1 ± 6.5 24.1 ± 10.2 24.9 ± 7.9
BMI: body mass index; X ± SD, *p < 0.05 versus pre.
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Table 3 cOmparisOn Of labOratOry data amOng the three grOups (cOntrOl, sOy and sOy + fibers)
Laboratory data
Control Group 
(Animal protein) 
(n = 9)
Study Group 1 
(Soy) 
(n = 9)
Study Group 2 
(Soy + Fibers) 
(n = 9)
Pre Post Pre Post Pre Post
Hemoglobin (g/dL)b  13.9 ± 1.5 14.6 ± 0.8 14.1 ± 1.5 13.4 ± 1.4* 13.2 ± 1.2 13.1 ± 1.9
Hematocritb    42.7 ± 4.8 44.1 ± 2.4 41.8 ± 4.5 40.1 ± 4.4 40.2 ± 3.8 40.3 ± 5.8
Sodium (g/d)b    139.0 ± 1.7 138.2 ± 2.6 137.2 ± 2.3 139.2 ± 1.8* 137.3 ± 2.4 138.1 ± 1.8
Potassium (mEq/d)b   4.4 ± 0.4 4.4 ± 0.3 4.5 ± 0.4 4.4 ± 0.1 4.4 ± 0.6 4.1 ± 0.4
Phosphorus (mEq/L)b 3.7 ± 0.3 3.7 ± 0.4 3.6 ± 0.5 3.8 ± 0.8 3.8 ± 0.5 3.6 ± 0.8
Albumin (g%)b 4.3 ± 0.3 4.3 ± 0.3 3.9 ± 0.7 3.9 ± 0.7 3.9 ± 0.7 3.9 ± 0.6
Triglycerides  
(mg/dL)b    
140.0 ± 80.6 127.1 ± 67.7 244.8 ± 275.9 181.2 ± 110.3 175.3 ± 145.5 163.4 ± 104.2
Cholesterol (mg/dL)b 200.9 ± 30.8 202.2 ± 29.4 234.0 ± 59.4 200.5 ± 34.0 240.9 ± 79.9 236.2 ± 80.2
HDL (mg/dL)b 55.5 ± 11.4 54.6 ± 14.1 67.1 ± 23.0 60.0 ± 20.3 58.5 ± 17.6 57.7 ± 19.6
VLDL (mg/dL)b   28.0 ± 16.0 25.5 ± 13.5 31.9 ± 20.6 36.4 ± 21.8 30.5 ± 18.2 32.62 ± 20.7
LDL (mg/dL)b      117.3 ± 24.1 122.1 ± 25.5 136.0 ± 59.1 104.1 ± 39.4 147.8 ± 73.3 145.9 ± 71.4
Iron (mg/d)b          79.5 ± 12.4 89.6 ± 22.6 85.2 ± 18.3 91.7 ± 24.8 79.7 ± 13.8 70.9 ± 20.7
Transferrin (mg/dL)b  249.4 ± 36.6 258.4 ± 32.4 228 ± 51.7 247.0 ± 41.4 240.3 ± 40.6 242.1 ± 39.9
Creatinine (mg/dL)b   1.1 ± 0.2 1.2 ± 0.3 1.0 ± 0.1 1.0 ± 0.1 1.1 ± 0.3 1.1 ± 0.3
CrCl (mL/min)   75 ± 27.1 79.1 ± 22.7 74.5 ± 27.3 73.6 ± 9.8 64.9 ± 17.4 67.6 ± 17.2
Urea (mg/dL)b   35.7 ± 12.7 35.6 ± 15.3 36.8 ± 13.5 31.7 ± 15.2* 36.4 ± 16.6 34.3 ± 11.2
Urea clearance  
(mL/min) 
42.9 ± 19.1 37.9 ± 14.1 33.5 ± 13.8 39.9 ± 13.6 35.4 ± 12.0 34.4 ± 13.1
Proteinuria  
(g/24-hour) 
0.7 ± 0.6 0.8 ± 0.6 2.0 ± 1.7 1.9 ± 1.8 2.0 ± 1.4 2.1 ± 2.0
Urinary sodium 
(mEq/L)   
201.5 ± 46.8 189.4 ± 78.1 151.9 ± 66.0 182.4 ± 77.7 162.4 ± 44.5 137.9 ± 37.0
Urinary phosphorus 
(mEq/L)      
658.1 ± 320.0 658.1 ± 298.7 551.3 ± 344.1 503.6 ± 234.8 530.9 ± 172.3 511 ± 157.6
X ± SD, *p < 0.05 versus pre;  b: blood determination.
Figure 1. Urinary protein in baseline and post diet periods in the three groups (Control, Soy and Soy + Fibers).
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Figure 2. Total cholesterol in baseline and post diet periods in the three groups (Control, Soy and Soy + Fibers).
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order to establish whether the patients were follow-
ing correctly the prescribed diet, a significant decrease 
in the energetic, lipids and protein intake in the three 
groups was observed. Although the food diary evalu-
ation has suggested an expressive decrease in food in-
gestion, according to the patients’ report during the 
period of study, significant changes were not observed 
in three groups when weight, BMI and body compo-
sition (body fat-free mass plus fat mass) were evalu-
ated, suggesting that the patients had an adequate diet 
ingestion during the period of study, and had not re-
ported their true food ingestion by the time of fulfill-
ing the food diary. When protein ingestion was eval-
uated by PNA, there was no significant decrease of 
intake in all groups; besides, the ingested amount was 
in accordance with the prescribed amount, reinforc-
ing the assumption that the patients have maintained 
an adequate protein ingestion during this study.
We also demonstrated that soy protein diet was 
safe to maintain the nutritional state (weight, BMI 
and body composition) of patients with proteinuric 
glomerulopathies, as well as APD in short-term. The 
ability of soy protein to warrant a good nutritional 
state can be justified by the fact that it is classified 
as a protein of high biological value, as it has all es-
sential amino acids in its composition similarly to 
the animal proteins.23
In rats, it seems to be well-established the ability 
of soy protein to reduce proteinuria and, consequent-
ly, to lower the progression of renal disease.4,24 Tovar 
et al.3 observed, in male Wistar rats that were receiv-
ing a soy protein diet (20%), a considerable recovery 
of creatinine clearance and a significant decrease in 
proteinuria compared with rats that were fed with 
casein (20%). Some investigators14,24,25 have shown 
lower renal damage and proteinuria in rats fed with 
soy protein than those with casein.
On the other hand, although the effect of soy pro-
tein is already well-established in rats, this statement 
is not true for humans. In humans, this issue was not 
yet carefully investigated, and there is a lot of contro-
versy about it. Some studies show positive results12,25-
28 and others show negative.12,29,30
Studies performed in healthy subjects have dem-
onstrated that substituting the APD by one of vegetal 
origin was efficient to prevent the proteinuric and hy-
perfiltration related effects of meat, which could be 
very advantageous in the treatment of subjects with 
chronic renal disease.13,31 On the contrary, Kitazato 
et al.30 have evaluated the effect of a diet with ele-
vated amount of vegetal protein and reduced content 
of animal protein and vice versa in healthy subjects, 
and they have not observed any difference of those 
diets on renal function and 24-hour urinary albumin 
excretion.
Soroka et al.29 have evaluated the effect of a low-
protein diet with vegetal protein compared to a low-
protein diet with animal protein in subjects with 
chronic renal failure, in a period of six months, and 
observed that although the vegetal protein diet had 
warranted better blood urea nitrogen levels, lower 
protein catabolic rate and lower 24-hour urinary 
levels of creatinine and phosphate, the urinary ex-
cretion of protein was similar in both diets. Serum 
levels of transferrin, albumin, and cholesterol were 
also similar.
Figure 3. Triglycerides in baseline and post diet periods in the three groups (Control, Soy and Soy + Fibers).
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Figure 4. LDL in baseline and post diet periods in the three groups (Control, Soy and Soy + Fibers).
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Some studies have suggested that the source of 
protein may affect the excretion of protein in subjects 
with diabetic nephropathy.32,33 Jibani et al.32 have 
compared the renal function in diabetic subjects with 
proteinuria, using a diet with animal protein versus a 
diet with vegetal protein. The last one has not affected 
glomerular filtration rate, but it has caused a signifi-
cant decrease in albumin excretion. Azadbakht et al.11 
have evaluated the effect of soy protein in comparison 
with animal protein on renal function, proteinuria, 
plasma cholesterol and TG, and they have observed 
that the soy diet was associated with significant de-
creases in the levels of cholesterol, TG, and protei-
nuria. On the contrary, Anderson et al.12 have com-
pared the effect of soy protein versus the animal one 
on renal function and proteinuria in type 2 diabetic 
subjects, and they verified that the soy protein diet 
determined a significant decrease only in cholesterol 
and TG concentration.
As previously mentioned, if we take in account 
that nephrotic patients develop numerous changes in 
the lipid profile, it would be very interesting to evalu-
ate the effect of soy protein, specifically in subjects 
with NS, not only due to its possible action on protein 
loss, but also due to the possibility of lowering choles-
terol and TG levels. Nevertheless, in the present study, 
when the effect of soy diet on the urinary excretion 
of protein and on serum total and LDL cholesterol 
levels and TG was evaluated, we have not observed 
significant changes in none of the groups between 
the baseline and post-diet periods. In opposition to 
the results found in this study, some investigators 
have observed that the soy protein was efficient to 
decrease proteinuria and plasma cholesterol in neph-
rotic syndrome.4,34,35 Gentile et al.34 and D’Amico 
et al.4 have observed that a eight-week soy protein 
diet decreased the proteinuria and hyperlipidemia in 
nephrotic patients with severe proteinuria.
Nevertheless, it should be emphasized that, in this 
study, it was not possible to determine if the favor-
able effect on proteinuria was due to the change of 
animal origin protein by soy protein or this effect was 
due to a significant decrease in the amount of protein 
ingested by the patients that received vegetal diet. In 
all these studies, the effect of soy protein on protei-
nuria in subjects with severe proteinuria was evalu-
ated. Herein, proteinuria was mainly evaluated in 
patients with low proteinuria levels. It is possible that 
the baseline low levels of proteinuria have prevented 
significant changes in the urinary excretion of pro-
teins, after ingestion of soy protein diet. In the present 
study, no marked decrease in cholesterol or TG levels 
was seen; it is also noteworthy that most of patients 
presented baseline and post-diet lipid levels within the 
range of reference values or very close to them. 
Finally, in the present study, no beneficial effects 
were observed when substituting animal protein by 
soy one for attenuating the glomerular injury, protei-
nuria and hyperlipidemia, but we concluded that the 
soy protein did not cause deleterious changes in body 
composition, warranting an adequate nutritional sta-
tus. Certainly, more studies involving short-term in-
gestion of soy protein in a higher number of patients 
are necessary to investigate the role of soy protein in 
proteinuric glomerulopathies. Although no beneficial 
effect was demonstrated in the groups evaluated, it 
was evident that the soy protein has adequately sub-
stituted the animal protein diet. The low number of 
cases could have explained the negative results related 
to the targets of this study. Besides, it would be more 
likely to find a positive effect of dietetic intervention 
with long-term use of soy protein, which will be ana-
lyzed in future studies.
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Quantity by portion    % VD (*)
Energy 150 kcal 6%
Carbohydrate 21 g 6%
Protein 10 g 20%
Total fat    3 g 4%
Saturated fat  0 g 0%
Cholesterol 0 mg 0%
Fiber 5 g 17%
Calcium 32 mg 4%
Iron 3 mg 21%
Sodium 0 mg 0%
OTHER MINERALS   
Phosphorus 260 mg 35%
Magnesium 64 mg 20%
Zinc 2,2 mg 15%
Copper 0,32 mg 10%
Mn 2,1 mg 40%
VITAMINS   
B1 0,3 mg 20%
B2 0,15 mg 10%
Niacine 1,2 mg 6%
A 136 mg 20%
D 2,5 mg 50%
appendiX a
nutritiOnal infOrmatiOn
pOrtiOn Of 40g
*VD: daily reference values based on a diet with 2,500 calories. 
Ingredients: Soy, Oat, wheat germ, brown sugar, cashew nut, 
raisin, and sesame.
appendiX b
nutritiOnal infOrmatiOn
pOrtiOn Of 30g
Quantity by portion   % VD (*)
Energy 110 kcal 4%
Carbohydrate 10 g 3%
Protein  17 g 34%
Total fat   0 g 0%
Saturated fat  0 g 0%
Cholesterol 0 mg 0%
Fiber 0 g 0%
Calcium 360 mg 45%
Iron 3 mg 20%
Sodium 85 mg 3%
OTHER MINERALS   
Phosphorus 290 mg 40%
Magnesium 30 mg 10%
Zinc 1 mg 7%
Copper 0,3 mg 10%
Mn 0,3 mg 6%
*Daily reference values based on a diet with 2,500 calories. 
Ingredients: soy protein, low fat powder milk, and calcium 
carbonate.
